Company news

Verastem, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

October 25, 2023

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

October 13, 2023

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

September 27, 2023

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

August 27, 2023

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 7, 2023

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

July 10, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

July 4, 2023

Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants

June 15, 2023

Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 14, 2023

Verastem Oncology Announces Reverse Stock Split

May 30, 2023

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

May 24, 2023

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

May 15, 2023

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 8, 2023

New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

April 25, 2023

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

April 17, 2023

New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

March 14, 2023

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

March 13, 2023

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

February 1, 2023

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

January 23, 2023

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

January 23, 2023

Verastem Oncology Appoints Rob Gagnon to Board of Directors

December 14, 2022

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 2, 2022

Verastem Oncology Appoints Anil Kapur to Board of Directors

October 19, 2022

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

October 3, 2022

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

August 7, 2022

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer

June 5, 2022

Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer

May 17, 2022

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 8, 2022

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

March 27, 2022

Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors

March 27, 2022

Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board

March 23, 2022

Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers

January 10, 2022

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer

November 21, 2021

Verastem Oncology to Present at the Jefferies London Healthcare Conference

November 10, 2021

Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

November 3, 2021

Verastem Oncology Appoints Michelle Robertson to Board of Directors

October 25, 2021

Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer

September 21, 2021

Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

September 19, 2021

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

September 18, 2021

Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 1, 2021

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021

July 26, 2021

Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

July 18, 2021

Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

June 23, 2021

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference

May 24, 2021

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

May 23, 2021

Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

May 10, 2021

Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022

March 17, 2021

Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference

March 1, 2021

Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology

January 19, 2021

Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

January 5, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 55 decks. Every deck is listed under its year.